Search research articles
Contact Us
Filters
Showing results (301-310 of 308) with videos related to
Page
of 31
Sort By:
You have reached the last page of results.
This site can display upto 308 results.
Asian Pacific Journal of Cancer Prevention : APJCP
|
August 21, 2012
A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China
Fang-Hui Zhao, Sarah M Tiggelaar, Shang-Ying Hu, et al.
Cancer Medicine
|
July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Cancer Epidemiology
|
March 2, 2012
A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China
Fang-Hui Zhao, Sarah M Tiggelaar, Shang-Ying Hu, et al.
Cancer Medicine
|
December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 2, 2025
Dynamic postoperative prognosis and follow-up optimization for gastric cancer patients after neoadjuvant therapy: a multicenter retrospective study
Qing Zhong, Zhi-Quan Zhang, Kai-Ning Ye, et al.
The Lancet. Infectious Diseases
|
June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial
Hong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
The Lancet. Infectious Diseases
|
August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Fang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
Journal of the National Cancer Institute
|
May 16, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial
You-Lin Qiao, Ting Wu, Rong-Cheng Li, et al.
Page
of 31
Search research articles
Search
Showing results (301-310 of 308) with videos related to
Sort By:
Page
of 31
You have reached the last page of results.
This site can display upto 308 results.
Asian Pacific Journal of Cancer Prevention : APJCP
|
August 21, 2012
A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China
Fang-Hui Zhao, Sarah M Tiggelaar, Shang-Ying Hu, et al.
Cancer Medicine
|
July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Cancer Epidemiology
|
March 2, 2012
A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China
Fang-Hui Zhao, Sarah M Tiggelaar, Shang-Ying Hu, et al.
Cancer Medicine
|
December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 2, 2025
Dynamic postoperative prognosis and follow-up optimization for gastric cancer patients after neoadjuvant therapy: a multicenter retrospective study
Qing Zhong, Zhi-Quan Zhang, Kai-Ning Ye, et al.
The Lancet. Infectious Diseases
|
June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial
Hong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
The Lancet. Infectious Diseases
|
August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Fang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
Journal of the National Cancer Institute
|
May 16, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial
You-Lin Qiao, Ting Wu, Rong-Cheng Li, et al.
Page
of 31